Published in N Engl J Med on December 20, 1990
Case reports in an evidence-based world. J R Soc Med (1999) 3.55
Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells. J Virol (1993) 2.93
Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86
The post-transplant lymphoproliferative disorder-a literature review. Pediatr Nephrol (2004) 1.92
Cancers complicating organ transplantation. N Engl J Med (1990) 1.57
Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis (2012) 1.47
Antibody immunosuppressive therapy in solid-organ transplant: Part I. MAbs (2011) 1.24
High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol (2000) 1.24
Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol (2011) 1.16
Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation. J Exp Med (1992) 1.06
Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci (1994) 1.06
The role of EBV in post-transplant malignancies: a review. J Clin Pathol (2000) 1.02
Plasma cell neoplasms in US solid organ transplant recipients. Am J Transplant (2013) 0.92
Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant (2011) 0.91
Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol (1999) 0.89
Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol (1995) 0.88
Cardiac retransplantation is an efficacious therapy for primary cardiac allograft failure. J Cardiothorac Surg (2008) 0.87
Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders. Am J Pathol (1997) 0.86
Advance modern medicine with clinical case reports. Quant Imaging Med Surg (2014) 0.86
Post-transplant lymphoproliferative disease. Pediatr Nephrol (2007) 0.86
Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Springer Semin Immunopathol (1998) 0.85
Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev (1997) 0.85
Active lymphocytic myocarditis treated with murine OKT3 monoclonal antibody in a patient presenting with intractable ventricular tachycardia. Tex Heart Inst J (2002) 0.84
Heart transplantation for dilated cardiomyopathy. Arch Dis Child (1995) 0.84
A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg (1996) 0.83
Antibody induction therapy in adult kidney transplantation: A controversy continues. World J Transplant (2012) 0.81
Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Liver Transpl (2013) 0.80
Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant (1992) 0.80
Lymphodepletional strategies in transplantation. Cold Spring Harb Perspect Med (2013) 0.78
Immunosenescence and organ transplantation. Transplant Rev (Orlando) (2013) 0.78
Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy. Am J Pathol (2002) 0.78
The challenge of rejection and cardiac allograft vasculopathy. Heart Fail Rev (2001) 0.78
Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center. Radiat Oncol (2010) 0.78
Immune disorders and susceptibility to neoplasms. Ochsner J (2002) 0.77
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
Monoclonal antibody therapy and renal transplantation: focus on adverse effects. Toxins (Basel) (2014) 0.77
Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience. Surg Today (2012) 0.77
Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget (2015) 0.76
Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level. World J Gastroenterol (2017) 0.75
Postoperative care of the transplanted patient. Curr Cardiol Rev (2011) 0.75
New immunosuppressive drugs in heart transplantation. Curr Control Trials Cardiovasc Med (2001) 0.75
The mother lode of liver transplantation, with particular reference to our new journal. Liver Transpl Surg (1998) 0.75
Basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years? Biologics (2009) 0.75
Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J Gastrointest Pathophysiol (2015) 0.75
The changing face of liver transplantation. Gut (1993) 0.75
EBV-associated recurrent Hodgkin's disease after renal transplantation. Transpl Int (2006) 0.75
Lowered Immune Cell Function in Liver Recipients Recovered From Posttransplant Lymphoproliferative Disease Who Developed Graft Tolerance. Transplant Direct (2016) 0.75
Post-transplantation lymphoproliferative disorder and OKT3. N Engl J Med (1991) 0.75
The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation. Eur J Clin Pharmacol (2017) 0.75
The influence of long-term morbidity on health status and rehabilitation following paediatric organ transplantation. Eur J Pediatr (1992) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 5.54
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med (1995) 3.56
A prospective, randomized study of cochlear implants. The Department of Veterans Affairs Cochlear Implant Study Group. N Engl J Med (1993) 3.54
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol (1990) 3.14
Inner-city residents, ethnic minorities and primary health care. Postgrad Med J (1983) 2.70
The development of smoking during adolescence--the MRC/Derbyshire Smoking Study. Int J Epidemiol (1983) 2.61
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol (2001) 2.47
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Improving classroom behavior in mentally retarded children through correspondence training. J Appl Behav Anal (1982) 2.39
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol (2008) 2.23
Acute cardiac events temporally related to cocaine abuse. N Engl J Med (1986) 2.18
Giant cell myocarditis: first report of disease recurrence in the transplanted heart. J Heart Lung Transplant (1992) 2.15
Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology (2008) 2.06
Response deprivation and reinforcement in applied settings: A preliminary analysis. J Appl Behav Anal (1980) 1.83
Procedural and methodological issues in telepsychiatry research and program development. Psychiatr Serv (2000) 1.78
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 1.76
Head-to-cervix force: an important physiological variable in labour. 2. Peak active force, peak active pressure and mode of delivery. Br J Obstet Gynaecol (1996) 1.75
The impact of substance use on mortality and morbidity from thermal injury. J Trauma (1995) 1.72
A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation (1995) 1.70
Head-to-cervix force: an important physiological variable in labour. 1. The temporal relation between head-to-cervix force and intrauterine pressure during labour. Br J Obstet Gynaecol (1996) 1.67
CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol (1993) 1.63
Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation (2001) 1.62
ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J (2006) 1.59
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther (1988) 1.58
Myocarditis confirmed by biopsy presenting as acute myocardial infarction. Br Heart J (1985) 1.56
Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. Int J Clin Pract (2013) 1.54
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
Endocardial infiltrates in the transplanted heart: clinical significance emerging from the analysis of 5026 endomyocardial biopsy specimens. J Heart Lung Transplant (1993) 1.52
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol (1996) 1.52
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol (1998) 1.51
Safety of patent ductus arteriosus closure in premature infants without tube thoracostomy. Ann Thorac Surg (1995) 1.51
Repeat organ transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.50
Placement of intra-aortic balloon pump allows definitive biliary surgery in patients with severe cardiac disease. Surgery (1989) 1.49
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol (1998) 1.48
A survey of hantavirus antibody in small-mammal populations in selected United States National Parks. Am J Trop Med Hyg (1998) 1.47
Simultaneous intracoronary ultrasound and Doppler flow studies distinguish flow-mediated from receptor-mediated endothelial responses. Catheter Cardiovasc Interv (1999) 1.46
Effect of dual tocolysis on the incidence of severe intraventricular hemorrhage among extremely low-birth-weight infants. Am J Obstet Gynecol (1996) 1.45
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am (1997) 1.45
Effects of dexamethasone on the hypothalamic-pituitary-adrenal axis in preterm infants. J Pediatr (1992) 1.45
Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. Circulation (1993) 1.42
The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci (1990) 1.42
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther (1992) 1.41
Cytomegalovirus infections in heart transplant recipients: relationship to immunosuppression. J Heart Lung Transplant (1992) 1.41
Evidence of impaired microvascular function in pre-eclampsia: a non-invasive study. Clin Sci (Lond) (2003) 1.41
Laboratory assays for the evaluation of recombinant hirudin. Haemostasis (1991) 1.40
Discordant epicardial and microvascular endothelial responses in heart transplant recipients early after transplantation. J Heart Lung Transplant (1998) 1.39
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma. Leuk Lymphoma (1998) 1.39
Clinical correlates of circulating immune complexes and antibody reactivity in squamous cell carcinoma of the head and neck. The Department of Veterans Affairs Laryngeal Cancer Study Group. J Clin Oncol (1993) 1.38
Birth weight: nature or nurture? Early Hum Dev (1995) 1.36
Visual estimates of percent diameter coronary stenosis: "a battered gold standard". J Am Coll Cardiol (1988) 1.36
The human T-cell leukemia-lymphoma virus in the southeastern United States. JAMA (1983) 1.34
The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain (2001) 1.32
Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg (2001) 1.30
The nonreceptor protein tyrosine phosphatase corkscrew functions in multiple receptor tyrosine kinase pathways in Drosophila. Dev Biol (1996) 1.29
Sensitivity and specificity of assessing coronary bypass graft patency with ultrafast computed tomography: results of a multicenter study. J Am Coll Cardiol (1988) 1.29
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med (1979) 1.28
Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant (1993) 1.26
Oestrogen receptors in human malignant melanoma. Lancet (1976) 1.26
Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res (1983) 1.25
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med (1983) 1.23
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. J Med Chem (1991) 1.23
Identification of a serine hydrolase as a key determinant in the microbial degradation of polychlorinated biphenyls. J Biol Chem (2000) 1.23
Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol (1988) 1.23
Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet (2004) 1.23
Endometrial thickness: a predictor of implantation in ovum recipients? Hum Reprod (1994) 1.22
Tripartite sequences within and 3' to the sea urchin H2A histone gene display properties associated with a transcriptional termination process. Mol Cell Biol (1986) 1.22
The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med (1988) 1.21
Accelerated angina pectoris. Clinical, hemodynamic, arteriographic, and therapeutic experience in 85 patients. Circulation (1973) 1.20
Aggressive treatment for postcardiac transplant lymphoproliferation. Blood (1995) 1.20
Reversal of advanced left ventricular dysfunction following aortic valve replacement for aortic stenosis. Ann Thorac Surg (1977) 1.20
Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res (2000) 1.19
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol (1989) 1.19
Evaluation of sperm washing as a potential method of reducing HIV transmission in HIV-discordant couples wishing to have children. AIDS (1999) 1.18
Some factors associated with increased risk of smoking by children. J Child Psychol Psychiatry (1983) 1.18
A self-instructional package for increasing attending behavior in educable mentally retarded children. J Appl Behav Anal (1980) 1.18
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology (2000) 1.17
Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol (2005) 1.17
Patients' fear of contracting the acquired immunodeficiency syndrome from physicians. Arch Intern Med (1990) 1.17
The gene for human liver arginase (ARG1) is assigned to chromosome band 6q23. Am J Hum Genet (1986) 1.17
Regulation of mRNA levels for five urea cycle enzymes in rat liver by diet, cyclic AMP, and glucocorticoids. Arch Biochem Biophys (1987) 1.16
Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol (1986) 1.16
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol (1993) 1.16